Biofil Chemicals and Pharmaceuticals Limited

BSE:524396 Stock Report

Market Cap: ₹967.8m

Biofil Chemicals and Pharmaceuticals Past Earnings Performance

Past criteria checks 1/6

Biofil Chemicals and Pharmaceuticals's earnings have been declining at an average annual rate of -21.1%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 2.4% per year. Biofil Chemicals and Pharmaceuticals's return on equity is 2.9%, and it has net margins of 1.7%.

Key information

-21.1%

Earnings growth rate

-21.7%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate2.4%
Return on equity2.9%
Net Margin1.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biofil Chemicals and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524396 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24315570
30 Jun 24460660
31 Mar 24404770
31 Dec 23384770
30 Sep 23349770
30 Jun 232026100
31 Mar 23300660
31 Dec 22181370
30 Sep 22182670
30 Jun 222937110
31 Mar 22224780
31 Dec 21354370
30 Sep 21370570
30 Jun 213961280
31 Mar 213581280
31 Dec 202601880
30 Sep 203561590
30 Jun 203121480
31 Mar 202981290
31 Dec 1928611100
30 Sep 193001190
30 Jun 19205590
31 Mar 19232590
31 Dec 18242590
30 Sep 18108590
30 Jun 1895490
31 Mar 18124570
31 Dec 1715114150
30 Sep 1718117150
30 Jun 172021950
31 Mar 171351850
31 Dec 1612213100
30 Sep 161529100
30 Jun 16130850
31 Mar 16132890
31 Dec 15119670
30 Sep 1559570
30 Jun 1561670
31 Mar 1559670
31 Dec 14686100
30 Sep 1466690
30 Jun 1468540
31 Mar 1472590
31 Dec 1371980

Quality Earnings: 524396 has high quality earnings.

Growing Profit Margin: 524396's current net profit margins (1.7%) are lower than last year (1.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524396's earnings have declined by 21.1% per year over the past 5 years.

Accelerating Growth: 524396's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524396 had negative earnings growth (-20.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).

Return on Equity

High ROE: 524396's Return on Equity (2.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 16:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biofil Chemicals and Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution